---
title: "Marvel Biosciences says MB-204 reverses cognitive, behavioral deficits in Fragile X mouse study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294936790.md"
description: "Marvel Biosciences reported positive preclinical results for MB-204 in a Fragile X mouse study. Two-week oral dosing restored behavioral and cognitive measures toward wild-type levels, with high doses showing the strongest effects. Benefits persisted post-treatment for locomotor activity and memory. These findings support advancing MB-204 toward clinical trials across ASD-related models."
datetime: "2026-08-05T09:00:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294936790.md)
  - [en](https://longbridge.com/en/news/294936790.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294936790.md)
generator: "portal-rs"
---

# Marvel Biosciences says MB-204 reverses cognitive, behavioral deficits in Fragile X mouse study

-   Marvel Biosciences reported positive preclinical results for MB-204 in a Fragile X (Fmr1 knockout) mouse study run via FRAXA-DVI. \* Two-week oral dosing restored all tested behavioral and cognitive measures toward wild-type levels; high dose showed the strongest, most consistent effects. \* Carry-over persisted two weeks post-treatment for high dose in locomotor activity, self-grooming, recognition memory; effects weakened versus on-treatment results. \* Data extend MB-204 efficacy across three ASD-related preclinical models, supporting advancement toward clinical trials and broader orphan-indication positioning. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marvel Biosciences Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050500PRIMZONEFULLFEED9803840) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

## Related News & Research

- [Marvel Biosciences expands private placement to Quebec investors](https://longbridge.com/en/news/296383510.md)
- [US Treasury buybacks a 'mistake' costing credibility, says Druckenmiller](https://longbridge.com/en/news/296868961.md)
- [DTL: Record sales, profit growth, and strategic AI investments drive strong performance](https://longbridge.com/en/news/296714206.md)
- [Xtract One CEO Evans flags “vanity metrics” in weapons detection, urges focus on capture rates](https://longbridge.com/en/news/296946614.md)
- [Syn ends talks with Asa on sale of web and radio media assets](https://longbridge.com/en/news/296710541.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**